Kura Oncology (KURA) Accounts Payables (2010 - 2026)
Kura Oncology (KURA) reported Accounts Payables of $7.0 million for Q1 2026, down 84.38% year-over-year from $45.1 million in Q1 2025, and up 40.38% on a QoQ basis from $5.0 million in Q4 2025.
Kura Oncology (KURA) has 17 years of Accounts Payables data on file, last reported at $7.0 million in Q1 2026.
- Quarterly Accounts Payables fell 84.38% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (down 84.38% YoY) and the FY2025 annual result came in at $5.0 million, up 241.52% from the prior year.
- Accounts Payables rose to $7.0 million in Q1 2026 per KURA's latest filing, from $5.0 million in the prior quarter.
- Across five years, Accounts Payables topped out at $45.1 million in Q1 2025 and bottomed at $1.3 million in Q1 2022.
- The 5-year median for Accounts Payables is $2.3 million (2023), against an average of $6.9 million.
- The widest annual swing landed in 2022, when Accounts Payables plunged 93.96%; it then surged 839.02% in 2024.
- Tracing KURA's Accounts Payables over 5 years: stood at $1.5 million in 2022, then soared by 50.03% to $2.3 million in 2023, then slumped by 36.13% to $1.5 million in 2024, then jumped by 241.52% to $5.0 million in 2025, then surged by 40.38% to $7.0 million in 2026.
- Per Business Quant, the three latest KURA Accounts Payables figures stand at $7.0 million (Q1 2026), $5.0 million (Q4 2025), and $4.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | 7.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.04 Mn |
| Dec 31, 2025 | 5.02 Mn |
| Sep 30, 2025 | 4.67 Mn |
| Jun 30, 2025 | 1.70 Mn |
| Mar 31, 2025 | 45.09 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | 3.01 Mn |
| Jun 30, 2024 | 2.06 Mn |
| Mar 31, 2024 | 30.90 Mn |
| Dec 31, 2023 | 2.30 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 2.34 Mn |
| Mar 31, 2023 | 3.29 Mn |
| Dec 31, 2022 | 1.53 Mn |
| Sep 30, 2022 | 1.75 Mn |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | 1.34 Mn |
| Dec 31, 2021 | 20.19 Mn |
| Sep 30, 2021 | 21.93 Mn |
| Jun 30, 2021 | 2.40 Mn |
| Mar 31, 2021 | 22.14 Mn |
| Dec 31, 2020 | 23.02 Mn |
| Sep 30, 2020 | 19.21 Mn |
| Jun 30, 2020 | 786,000.00 |
| Mar 31, 2020 | 2.45 Mn |
| Dec 31, 2019 | 3.53 Mn |
| Sep 30, 2019 | 12.87 Mn |
| Jun 30, 2019 | 10.88 Mn |
| Mar 31, 2019 | 11.78 Mn |
| Dec 31, 2018 | 3.94 Mn |
| Sep 30, 2018 | 1.84 Mn |
| Jun 30, 2018 | 9.33 Mn |
| Mar 31, 2018 | 2.10 Mn |
| Dec 31, 2017 | 8.28 Mn |
| Sep 30, 2017 | 6.20 Mn |
| Jun 30, 2017 | 4.18 Mn |
| Mar 31, 2017 | 598,000.00 |
| Dec 31, 2016 | 4.68 Mn |
| Sep 30, 2016 | 4.18 Mn |
| Jun 30, 2016 | 199,000.00 |
| Mar 31, 2016 | 3.12 Mn |
| Dec 31, 2015 | 902,000.00 |
| Sep 30, 2015 | 407,000.00 |
| Jun 30, 2015 | 715,000.00 |
| Mar 31, 2015 | 1.06 Mn |
| Dec 31, 2014 | 846,000.00 |
| Sep 30, 2014 | 10,682.00 |
| Jun 30, 2014 | 8,155.00 |
| Mar 31, 2014 | 713.00 |
| Dec 31, 2013 | 350.00 |
| Sep 30, 2013 | 650.00 |
| Jun 30, 2013 | 175.00 |
| Mar 31, 2013 | 6,290.00 |
| Dec 31, 2012 | 1,850.00 |
| Sep 30, 2012 | 633.00 |
| Jun 30, 2012 | 175.00 |
| Mar 31, 2012 | 3,816.00 |
| Dec 31, 2011 | 2,927.00 |
| Sep 30, 2011 | 2,497.00 |
| Jun 30, 2011 | 2,200.00 |
| Mar 31, 2011 | 2,927.00 |
| Dec 31, 2010 | 2,165.00 |